{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:18:55Z","timestamp":1792725535176,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T00:00:00Z","timestamp":1489363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jad-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jad.2017.03.032","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T09:33:39Z","timestamp":1489052019000},"page":"205-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II\/III studies"],"prefix":"10.1016","volume":"215","author":[{"given":"Willie","family":"Earley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Durgam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Debelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Laszlovszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi N.","family":"Yatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2017.03.032_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders,","author":"APA","year":"2000"},{"key":"10.1016\/j.jad.2017.03.032_bib2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4088\/JCP.v68n0614","article-title":"The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study","volume":"68","author":"Birkenaes","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study","volume":"76","author":"Calabrese","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib5","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/14656566.2012.656590","article-title":"Treatment-emergent adverse events associated with atypical antipsychotics","volume":"13","author":"Cha","year":"2012","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.jad.2017.03.032_bib6","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s12272-010-1005-8","article-title":"Current perspectives on the selective regulation of dopamine D(2) and D(3) receptors","volume":"33","author":"Cho","year":"2010","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jad.2017.03.032_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S1461145709990344","article-title":"Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis","volume":"13","author":"Cruz","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.03.032_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2017.03.032_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2017.03.032_bib10","doi-asserted-by":"crossref","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression","volume":"173","author":"Durgam","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/YCO.0b013e328333e132","article-title":"An update of evidence-based treatment of bipolar depression: where do we stand?","volume":"23","author":"Fountoulakis","year":"2010","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib13","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2017.03.032_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-642-25758-2_7","article-title":"The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions","author":"Gross","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jad.2017.03.032_bib15","series-title":"The Abnormal Movement Scale, ECDEU Assessment Manual for Psychopharmacology","first-page":"218","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2017.03.032_bib16","series-title":"The Clinician Global Severity and Impression Scales. ECDEU Assessment Manual for Psychopharmacology","first-page":"218","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2017.03.032_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00210-008-0311-x","article-title":"Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15","volume":"378","author":"Gyertyan","year":"2008","journal-title":"Naunyn Schmiede. Arch. Pharm."},{"key":"10.1016\/j.jad.2017.03.032_bib18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4088\/JCP.08r04210","article-title":"Akathisia: an updated review focusing on second-generation antipsychotics","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial","volume":"35","author":"Kane","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.03.032_bib20","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/0269881109348157","article-title":"Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials","volume":"24","author":"Kane","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.03.032_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00210-008-0308-5","article-title":"Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: i. neurochemical characterisation of RG-15","volume":"378","author":"Kiss","year":"2008","journal-title":"Naunyn Schmiede. Arch. Pharmacol."},{"key":"10.1016\/j.jad.2017.03.032_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2017.03.032_bib23","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.4088\/JCP.10m06347yel","article-title":"Bipolar disorder: new perspectives in health care and prevention","volume":"71","author":"Leboyer","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2012.04.003","article-title":"Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system","volume":"135","author":"Leung","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jad.2017.03.032_bib25","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1517\/14656566.2010.510835","article-title":"Atypical antipsychotic tolerability and switching strategies in bipolar disorder","volume":"11","author":"Liauw","year":"2010","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.jad.2017.03.032_bib26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/DDDT.S95100","article-title":"Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)","volume":"10","author":"Nakamura","year":"2016","journal-title":"Drug Des. Dev. Therapy"},{"key":"10.1016\/j.jad.2017.03.032_bib28","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.euroneuro.2015.04.007","article-title":"Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice","volume":"25","author":"Pacchiarotti","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.03.032_bib29","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib30","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1177\/0269881112463127","article-title":"Histamine and antipsychotic drug-induced weight gain","volume":"26","author":"Reynolds","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2017.03.032_bib31","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4088\/JCP.10ac06470yel","article-title":"New antipsychotic drugs: how do their receptor-binding profiles compare?","volume":"71","author":"Richelson","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","article-title":"Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial","volume":"174","author":"Sachs","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2017.03.032_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.jad.2017.03.032_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/15622970601083280","article-title":"Evolving trends in the long-term treatment of bipolar disorder","volume":"8","author":"Vieta","year":"2007","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2017.03.032_bib35","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.euroneuro.2015.08.020","article-title":"Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II\/III trials","volume":"25","author":"Vieta","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2017.03.032_bib36","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/npp.2010.192","article-title":"Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials","volume":"36","author":"Yildiz","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2017.03.032_bib37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032716321632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032716321632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T19:21:08Z","timestamp":1658776868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032716321632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":37,"alternative-id":["S0165032716321632"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2017.03.032","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II\/III studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2017.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}